NCT04685811View on ClinicalTrials.gov

Evaluation of PSMA Antagonist Produced by Two Different Methods

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Metastatic Prostate Adenocarcinoma
Interventions
DRUG

68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron

68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.

Trial Locations (1)

10021

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT04685811 - Evaluation of PSMA Antagonist Produced by Two Different Methods | Biotech Hunter | Biotech Hunter